---
schema_version: "secwatch.filing_event.v1"
accession: "0001937653-25-000047"
form_type: "8-K"
ticker: "ZYME"
cik: "0001937653"
company_name: "Zymeworks Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:27:07.248277+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zymeworks posts Q2 net income of $2.3M on revenue of $48.7M; cash runway into 2H-2027

## Summary
- Revenue of $48.7M in Q2 2025 vs $19.2M in Q2 2024, driven by $20M BeOne milestone and $7.5M BMS license option.
- Net income of $2.3M compared to net loss of $37.7M in Q2 2024; R&D expenses $34.4M, G&A $15.0M.
- Cash resources $333.4M as of June 30, 2025, projected to fund operations into 2H-2027 with anticipated milestones.
- FDA cleared IND for ZW251 (GPC3-targeting ADC); Phase 1 planned for 2025, joining ZW171 and ZW191 in clinic.
- Jazz reported Ziihera net sales of $5.5M in Q2; conditional EU approval for HER2+ BTC and China approval noted.

## SEC filing metadata
- accession: 0001937653-25-000047
- form_type: 8-K
- ticker: ZYME
- cik: 0001937653
- company_name: Zymeworks Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000047/0001937653-25-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1937653/000193765325000047/zyme-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001937653-25-000047
- JSON: https://secwatch.observer/filing/0001937653-25-000047.json
- Plain text: https://secwatch.observer/filing/0001937653-25-000047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.